SuperworthCVRx CVRX
- Market cap
- $37.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $61.2M
- +12% on a year ago
- Net margin
- −84.9%
- Free cash flow yield
- −108.5%
CVRx trades at 0.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $61.2M over the last twelve months, up 12% on a year earlier with a −85% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.5M+70% | $11.3M+58% | $10.8M+35% | $11.8M+24% | $13.4M+27% | $15.3M+36% | $12.3M+15% | $13.6M+15% | $14.7M+10% | $16M+4% | $14.8M+20% | $15.7M+16% | |
| Cost of revenue | $1.7M+26% | $1.7M+14% | $1.6M+22% | $1.9M+25% | $2.2M+33% | $2.6M+50% | $2M+26% | $2.1M+13% | $1.9M−14% | $2.2M−15% | $1.9M−7% | $2M−7% |
| Gross profit | $8.8M+82% | $9.6M+69% | $9.2M+38% | $9.9M+24% | $11.1M+26% | $12.8M+33% | $10.3M+13% | $11.4M+16% | $12.8M+15% | $13.8M+8% | $12.9M+25% | $13.7M+20% |
| R&D | $2.7M+18% | $2.2M−26% | $3.1M−11% | $2.8M−16% | $2.5M−7% | $2.8M+25% | $2.5M−18% | $2.5M−11% | $3.1M+26% | $3M+7% | $3.1M+23% | $3.1M+27% |
| SG&A | $15.7M+23% | $17M+21% | $28.3M+84% | $21.1M+28% | $21.6M+38% | $20.2M+19% | $21.2M−25% | $23.4M+11% | $21.9M+1% | $22M+9% | $22M+3% | $23.6M+1% |
| −$9.5M−6% | −$9.7M−16% | −$22.2M+83% | −$14M+19% | −$13M+37% | −$10.3M+6% | −$13.4M−40% | −$14.4M+3% | −$12.3M−6% | −$11.2M+9% | −$12.2M−10% | −$13M−9% | |
| Interest expense | $499K | $579K+251% | $960K+300% | $959K+99% | $958K+92% | $1.5M+163% | $1.5M+52% | $1.5M+54% | $1.5M+55% | $1.4M−7% | $1.6M+7% | $1.6M+7% |
| Pre-tax income | −$9M−8% | −$9.1M−13% | −$22.1M+95% | −$14M+20% | −$13.1M+46% | −$10.7M+18% | −$13.8M−38% | −$14.7M+5% | −$12.9M−1% | −$11.9M+11% | −$13.1M−5% | −$14M−5% |
| $40K+25% | $39K+39% | $38K+12% | $41K+21% | $47K+18% | −$71K | −$5K | −$3K | −$3K | −$7K−90% | $1K | $3K | |
| Net income | −$9M−8% | −$9.2M−13% | −$22.2M+95% | −$14M+20% | −$13.1M+45% | −$10.7M+16% | −$13.8M−38% | −$14.7M+5% | −$12.9M−2% | −$11.9M+12% | −$13.1M−5% | −$14M−5% |
| −$0.43−10% | −$0.44−14% | −$1.04+89% | −$0.65+16% | −$0.57+33% | −$0.43−2% | −$0.53−49% | −$0.57−12% | −$0.49−14% | −$0.46+7% | −$0.50−6% | −$0.53−7% | |
| 20.8M+1% | 20.8M+1% | 21.2M+3% | 21.6M+4% | 22.8M+10% | 24.7M+19% | 25.9M+22% | 26.1M+21% | 26.2M+15% | 26.2M+6% | 26.4M+2% | 26.5M+2% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest CVRx's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CVRXCVRx | $37.8M | n/m | n/a | 0.6× | +12% | −84.9% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| Peer median | $147.1M | 18.6× | 18.7× | 1.9× | +6% | 7.6% |
More on CVRx
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .